The rebate program begins in April and can save Medicare recipients anywhere from $2 to $390, the White House said. MORE ⬇️
The White House announced Wednesday that 27 different drugs will now be subject to Medicare Part B rebates because their prices increased faster than the rate of inflation
Although Medicare recipients will start seeing savings in April, the drug companies won’t be invoiced for the rebates until 2025. The rebates will be paid to the Medicare Trust Fund.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
US to impose inflation fines on first set of drugs, lowering costsThe U.S. government will subject 27 drugs to inflation penalties, it announced on Wednesday, meaning people on Medicare will pay less out-of-pocket by $2 to as high as $390 per average dose starting April 1.
Weiterlesen »
Biden to tout prescription drug plan, budget proposal in Las VegasThe president’s budget proposal is a largely ceremonial document that lays out the Biden administration’s vision before negotiations begin with a Republican-controlled House of Representatives.
Weiterlesen »
Fearing Backlash, Republicans Backpedal on Social Security and Medicare CutsTrump is opportunistically exploiting rifts within the GOP over the prospect of cutting Social Security and Medicare.
Weiterlesen »
Veterans to get coverage of Alzheimer's drug Medicare won't pay forThe Veterans Health Administration said that it intends to pay for a $26,500-a-year experimental Alzheimer's drug that the Centers for Medicare and Medicaid Services has to date declined to cover.
Weiterlesen »
Economists Warn of Costs if US Medicare Covers New Obesity DrugsThe cost of expanding US Medicare prescription drug coverage to pay for expensive, new obesity medications could be catastrophic, health economists warned in a report published on Saturday.
Weiterlesen »
Economists warn of costs if US Medicare covers new obesity drugsThe cost of expanding U.S. Medicare prescription drug coverage to pay for expensive, new obesity medications could be catastrophic, health economists warned in a report published on Saturday.
Weiterlesen »